Taselisib [19–21], a novel selective inhibitor of mutant PI3Kα and ipatasertib (GDC-0068) [22–25], an inhibitor of all three AKT isoforms with a specific activity on mutant AKT1, are currently under development in phase II and III clinical trials in combination with paclitaxel or hormonal therapy in different setting of BC therapy (NCT02301988, NCT02162719, NCT02340221, NCT02273973, NCT01296555 and NCT01862081). Here, AKT1 is linked to breast cancer.